Description: F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star’s mission is to generate highly differentiated best-in-class drug candidates with monoclonal antibody-like manufacturability.
Home Page: www.f-star.com
FSTX Technical Analysis
Eddeva B920
Cambridge,
CB22 3AT
United Kingdom
Phone:
44 1223 497400
Officers
| Name | Title |
|---|---|
| Dr. Eliot Richard Forster M.B.A., Ph.D. | Pres, CEO & Director |
| Ms. Darlene M. Deptula-Hicks MBA | CFO, Treasurer & Sec. |
| Dr. Neil Brewis Ph.d. | Chief Scientific Officer |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer |
| Lindsey Trickett | VP of Investor Relations & Communications |
| Mr. James Sandy MPhil | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1272 |
| Price-to-Sales TTM: | 5.4708 |
| IPO Date: | 2016-05-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 84 |